These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15878442)

  • 1. Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens.
    Lodise TP; Preston S; Bhargava V; Bryskier A; Nusrat R; Chapel S; Rangaraju M; Drusano GL
    Diagn Microbiol Infect Dis; 2005 May; 52(1):45-52. PubMed ID: 15878442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic analysis of the microbiological efficacy of telithromycin in patients with community-acquired pneumonia.
    Shi J; Pfister M; Jenkins SG; Chapel S; Barrett JS; Port RE; Howard D
    Clin Pharmacokinet; 2005; 44(3):317-29. PubMed ID: 15762772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
    Tellier G; Niederman MS; Nusrat R; Patel M; Lavin B
    J Antimicrob Chemother; 2004 Aug; 54(2):515-23. PubMed ID: 15269191
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Flamm RK; Rhomberg PR; Sader HS
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
    Walsh F; Carnegy F; Willcock J; Amyes S
    J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
    Felmingham D
    J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacteriological efficacy of 5-day therapy with telithromycin in acute maxillary sinusitis.
    Buchanan P; Roos K; Tellier G; Rangaraju M; Leroy B
    Int J Antimicrob Agents; 2005 Mar; 25(3):237-46. PubMed ID: 15737519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
    Pfaller MA; Farrell DJ; Sader HS; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Germany and activity of the Ketolide Telithromycin: results from the PROTEKT surveillance study (1999-2000).
    Reinert RR; Rodloff AC; Halle E; Baer W; Beyreiss B; Seifert H; Wichelhaus TA; Maass M; Mehl M
    Chemotherapy; 2004 Jun; 50(3):143-51. PubMed ID: 15272227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of telithromycin against respiratory tract pathogens in comparison with other antimicrobial agents.
    Ling TK; Lee CC
    Chemotherapy; 2005 Jul; 51(4):182-5. PubMed ID: 15980628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
    Biedenbach DJ; Farrell DJ; Flamm RK; Liverman LC; McIntyre G; Jones RN
    Int J Antimicrob Agents; 2012 Apr; 39(4):321-5. PubMed ID: 22306239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of resistance of telithromycin against Haemophilus influenzae, Moraxella catarrhalis and streptococci in comparison with macrolides.
    Drago L; De Vecchi E; Nicola L; Colombo A; Gismondo MR
    J Antimicrob Chemother; 2004 Aug; 54(2):542-5. PubMed ID: 15215227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of a novel series of acylides active against community-acquired respiratory pathogens.
    Pandya M; Chakrabarti A; Rathy S; Katoch R; Venkataraman R; Bhateja P; Mathur T; Kumar GR; Malhotra S; Rao M; Bhadauria T; Barman TK; Das B; Upadhyay D; Bhatnagar PK
    Int J Antimicrob Agents; 2010 Aug; 36(2):169-74. PubMed ID: 20493666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study.
    Fogarty CM; Patel TC; Dunbar LM; Leroy BP
    BMC Infect Dis; 2005 May; 5():43. PubMed ID: 15927060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for treating community-acquired lower respiratory tract infections with amoxicillin/sulbactam combination through pharmacodynamic analysis in the setting of aminopenicillin-resistant organisms.
    Bantar C; Nicola F; Fernandez Canigia L; Arenoso HJ; Soutric J; Montoto M; Blanco M; Smayevsky J; Jasovich A
    J Chemother; 2001 Aug; 13(4):402-6. PubMed ID: 11589483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia.
    Hagberg L; Torres A; van Rensburg D; Leroy B; Rangaraju M; Ruuth E
    Infection; 2002 Dec; 30(6):378-86. PubMed ID: 12478329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods.
    Morrissey I; Robbins M; Viljoen L; Brown DF
    J Antimicrob Chemother; 2005 Feb; 55(2):200-8. PubMed ID: 15649996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis.
    Yoshida K; Okimoto N; Kishimoto M; Fukano H; Hara H; Yoneyama H; Moriya O; Kawanishi M; Kimura M; Matsushima T; Niki Y
    J Infect Chemother; 2011 Oct; 17(5):678-85. PubMed ID: 21847518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
    Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.